Parishin B
Based on 1 publication(s) in Google Scholar
Parishin B is a multi-target biological agent with anti-epileptic, anti-fascioliasis and anti-breast cancer lung metastasis activities. Parishin B regulates the gene/protein activities of ACLY, unc13c, γ-aminobutynergic system, pro-inflammatory system, antioxidant system, monoaminergic system, ferroptosis-related pathways, as well as GST, CatL, Trx and TRIB3. Parishin B modulates energy-lipid metabolism, synaptic function, neurotransmitter balance, neuroinflammation, oxidative stress, parasite detoxification/invasion processes, as well as apoptosis, cell cycle, proliferation and metastasis of cancer cells[1][2][3]. Parishin B can be used for related research of epilepsy, fascioliasis and breast cancer lung metastasis[3].
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.42%
- CAS. Nr.: 174972-79-3
- Formel: C32H40O19
- Molecular Weight:728.65
-
Speicherung:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Antioxidant Compound Library
HY-L037
-
Glycoside Compound Library
HY-L042
-
Medicine Food Homology Compound Library
HY-L055
-
Phenols Library
HY-L057
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Anti-Cancer Natural Product Library
HY-L107
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
Heterocyclic Compound Library
HY-L138
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Miao Ethnicity Medicine Compound Library
HY-L190
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Lactylation Compound Library
HY-L249
-
Mass Spectrometry Natural Product Library
HY-L262
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
NF-κB Signaling Compound Library
HY-L014
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
Publications Citing Use of MedChemExpress (MCE) Parishin B
More
Biologische Aktivität
Parishin B (10 μM; 1 h) increases the thermal stability of TRIB3 in MDA-MB-231 cell lysate, confirming direct binding to the protein[3].
Parishin B (20 μM; 24 h) blocks the TRIB3-AKT1 protein-protein interaction in MDA-MB-231 breast cancer cells[3].
Parishin B (0-120 μM; 48 h) selectively reduces viability in MDA-MB-231, SK-BR-3, MCF-7, HCC1954, and T-47D breast cancer cells with minimal toxicity to MCF-10A normal mammary epithelial cells[3].
Parishin B (5-20 μM; 12 day) suppresses colony formation in MDA-MB-231 breast cancer cells, reducing colony numbers by ~50% at 20 μM[3].
Parishin B (2.5-5 μM; 24 h) significantly reduces the migratory and invasive capabilities of MDA-MB-231 breast cancer cells, with ~80% inhibition of both processes at 5 μM[3].
Parishin B (5-20 μM; 24 h) induces concentration-dependent apoptosis in MDA-MB-231 breast cancer cells, with a ~40% apoptosis rate at 20 μM[3].
Parishin B (20 μM; 24 h) alters the gene expression profile of MDA-MB-231 breast cancer cells, with significant enrichment of DEGs in the cell cycle signaling pathway[3].
Parishin B (5-20 μM; 24 h) induces concentration-dependent G2/M phase arrest in MDA-MB-231 breast cancer cells, with ~50% of cells in G2/M at 20 μM[3].
Parishin B (5-20 μM; 24 h) upregulates CDK1 and Cyclin B1 expression, and increases PI3K and AKT1 phosphorylation levels, in MDA-MB-231 breast cancer cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231, SK-BR-3, MCF-7, HCC1954, T-47D breast cancer cells, MCF-10A normal mammary epithelial cells
-
Concentration:1.25 μM; 2.5 μM; 5 μM; 10 μM; 20 μM; 40 μM; 80 μM;120 μM
-
Incubation Time:24 h; 48 h
-
Result:Reduced viability in all tested breast cancer cell lines, with the strongest effects observed in MDA-MB-231 and MCF-7 cells.
Showed minimal toxicity to MCF-10A normal mammary epithelial cells at concentrations up to 120 μM, indicating selective cytotoxicity toward cancer cells.
-
Cell Line:MDA-MB-231 breast cancer cells
-
Concentration:5-20 μM
-
Incubation Time:24 h
-
Result:Induced apoptosis in MDA-MB-231 cells in a concentration-dependent manner, with apoptosis rates reaching ~15% at 5 μM, ~30% at 10 μM, and ~40% at 20 μM.
-
Cell Line:MDA-MB-231 breast cancer cells
-
Concentration:5-20 μM
-
Incubation Time:12 day
-
Result:Significantly suppressed colony formation in MDA-MB-231 cells, reducing colony numbers by ~20% at 5 μM, ~20% at 10 μM, and ~50% at 20 μM compared to control.
-
Cell Line:MDA-MB-231 breast cancer cells
-
Concentration:2.5-5 μM
-
Incubation Time:24 h
-
Result:Significantly reduced the migratory capacity of MDA-MB-231 cells, reducing relative migration by ~50% at 2.5 μM and ~80% at 5 μM.
Significantly reduced invasive capacity, reducing relative invasion by ~50% at 2.5 μM and ~80% at 5 μM.
-
Cell Line:MDA-MB-231 breast cancer cells
-
Concentration:5-20 μM
-
Incubation Time:24 h
-
Result:Induced a concentration-dependent G2/M phase arrest in MDA-MB-231 cells, with the percentage of cells in G2/M increasing from ~15% in control to ~20% at 5 μM, ~30% at 10 μM, and ~50% at 20 μM.
-
Cell Line:MDA-MB-231 breast cancer cells
-
Concentration:5-20 μM
-
Incubation Time:24 h
-
Result:Increased the expression of CDK1 and Cyclin B1 in a concentration-dependent manner, with significant upregulation observed at 10 μM and 20 μM.
Increased the phosphorylation levels of PI3K (Tyr458) and AKT1 (Ser473) in a concentration-dependent manner, with significant increases observed at 10 μM and 20 μM.
Parishin B (0.0625-0.25 mg/mL; immersion; continuous; 5 days) causes no apparent developmental toxicity or behavioral impairment in zebrafish embryos[1].
Parishin B (4-8 mg/kg; i.p.; once a day; 6 weeks) inhibits breast cancer lung metastasis in female BALB/c nude mice in vivo in a dose-dependent manner, with the 8 mg/kg daily intraperitoneal dose reducing average lung tumor nodule number by ~55% and lung fluorescence flux by ~67%, while upregulating AKT/PI3K phosphorylation and Cyclin B1/CDK1 expression in lung tissues without causing detectable toxicity[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:wild-type AB strain (7 days post-fertilization larvae)[1]
-
Dosage:0.0625 mg/mL; 0.125 mg/mL; 0.25 mg/mL
-
Administration:immersion; 60 min
-
Result:Significantly reduced PTZ-induced hyperlocomotion, including total swimming distance and average swimming speed (p < 0.05, p < 0.01) compared to the PTZ-only group.
Significantly increased GABA (p < 0.05, p < 0.001), dopamine (p < 0.001), and norepinephrine (p < 0.01, p < 0.001, p < 0.0001) levels, while reducing elevated 5-HT levels (p < 0.05, p < 0.001) compared to the PTZ-only group; did not significantly alter glutamate levels.
Exerted dose-dependent anti-inflammatory effects: at 0.125 mg/mL, reduced IL-1β levels more effectively than the positive control VPA (p < 0.0001), partially restored PTZ-reduced IL-6 levels (p < 0.001, p < 0.0001), and suppressed PTZ-increased TNF-α levels.
Significantly increased superoxide dismutase (SOD) activity at all tested doses (p < 0.0001), with effects superior to VPA.
Partially normalized PTZ-induced global metabolic alterations at 0.125 mg/mL, restoring key energy metabolism metabolites (e.g., inositol, Alpha-D-glucose) and reversing lipid accumulation.
Reversed PTZ-induced proteomic dysregulation at 0.125 mg/mL, stabilizing cytoskeleton proteins, restoring synaptic protein (unc-13) homeostasis, and upregulating ATP-citrate lyase (ACLY).
Upregulated GABAergic signaling genes (gad2, slc32a1, gabra1), synaptic priming gene unc13c, and metabolic regulatory gene aclya (p < 0.001, p < 0.0001); suppressed pro-inflammatory genes (il1b, tnfa, nfkb1) (p < 0.05, p < 0.001, p < 0.0001); upregulated oxidative stress and mitochondrial function genes (sod1, gpx1a, ndufs1, ucp2) (p < 0.001, p < 0.0001); and suppressed monoaminergic neurotransmitter metabolism genes (th, dbh, tph1a, tph2) (p < 0.05, p < 0.001, p < 0.0001).
-
Animal Model:BALB/c nude (female, 4-5 weeks old, breast cancer lung metastasis model via tail vein injection of MDA-MB-231-LUC cells)[3]
-
Dosage:4 mg/kg; 8 mg/kg
-
Administration:i.p.; once a day; 6 weeks
-
Result:Reduced average lung tumor nodule number from ~11 to ~7 (4 mg/kg) and from ~11 to ~5 (8 mg/kg).
Reduced lung fluorescence flux from ~6 × 106 p/s to ~3 × 106 p/s (4 mg/kg) and from ~6 × 106 p/s to ~2 × 106 p/s (8 mg/kg).
Increased relative phosphorylation levels of AKT by 1.8-fold (4 mg/kg) and 2.0-fold (8 mg/kg) relative to controls.
Increased relative phosphorylation levels of PI3K by 1.4-fold (4 mg/kg) and 1.8-fold (8 mg/kg) relative to controls.
Increased relative expression of Cyclin B1 by 1.7-fold (4 mg/kg) and 1.9-fold (8 mg/kg) relative to controls.
Increased relative expression of CDK1 by 1.9-fold (4 mg/kg) and 2.8-fold (8 mg/kg) relative to controls.
Showed marked improvement in pulmonary metastatic lesions via H&E staining in both treated groups compared to controls.
Caused no significant drug toxicity, with all organ indices remaining within normal ranges.
Chemical Information
-
CAS. Nr. 174972-79-3
-
Appearance Solid
-
Molecular Weight 728.65
-
Formel C32H40O19
-
Color White to off-white
-
SMILES
O=C(OCC1=CC=C(O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO)O2)O)O)O)C=C1)CC(O)(CC(O)=O)C(OCC3=CC=C(O[C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO)O4)O)O)O)C=C3)=O
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
Lösungsmittel & Löslichkeit
DMSO : 50 mg/mL (68.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 50 mg/mL (68.62 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.43 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.43 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Reinheit & Dokumentation
-
Data Sheet (288 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[4]. Cheng X, et al. An Optimized and Sensitive Pharmacokinetic Quantitative Method of Investigating Gastrodin, Parishin, and Parishin B, C and E in Beagle Dog Plasma using LC-MS/MS after Intragastric Administration of Tall Gastrodia Capsules. Molecules. 2017 Nov 10;22(11):1938. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 1.3724 mL | 6.8620 mL | 13.7240 mL | 34.3100 mL |
| 5 mM | 0.2745 mL | 1.3724 mL | 2.7448 mL | 6.8620 mL | |
| 10 mM | 0.1372 mL | 0.6862 mL | 1.3724 mL | 3.4310 mL | |
| 15 mM | 0.0915 mL | 0.4575 mL | 0.9149 mL | 2.2873 mL | |
| 20 mM | 0.0686 mL | 0.3431 mL | 0.6862 mL | 1.7155 mL | |
| 25 mM | 0.0549 mL | 0.2745 mL | 0.5490 mL | 1.3724 mL | |
| 30 mM | 0.0457 mL | 0.2287 mL | 0.4575 mL | 1.1437 mL | |
| 40 mM | 0.0343 mL | 0.1716 mL | 0.3431 mL | 0.8578 mL | |
| 50 mM | 0.0274 mL | 0.1372 mL | 0.2745 mL | 0.6862 mL | |
| 60 mM | 0.0229 mL | 0.1144 mL | 0.2287 mL | 0.5718 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Parishin B Related Classifications
HY-N2124 Related Classifications
Powered by Bioz